Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 4/20 | 0.40 |
| ▸ | GAA | P10253 | 3/20 | 0.40 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.40 |
| ▸ | MAPT | P10636 | 3/20 | 0.40 |
| ▸ | MEN1 | O00255 | 2/20 | 0.40 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.40 |
| ▸ | MTNR1A | P48039 | 1/20 | 0.39 |
| ▸ | MTNR1B | P49286 | 1/20 | 0.39 |
| ▸ | AKR1C2 | P52895 | 1/20 | 0.39 |
| ▸ | PTGDR2 | Q9Y5Y4 | 5/20 | 0.39 |
| ▸ | PTGDR | Q13258 | 4/20 | 0.39 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.38 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.38 |
| ▸ | PPARD | Q03181 | 3/20 | 0.37 |
| ▸ | PPARG | P37231 | 3/20 | 0.36 |
| ▸ | CA2 | P00918 | 1/20 | 0.36 |
| ▸ | HPGD | P15428 | 1/20 | 0.36 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.36 |
| ▸ | PPARA | Q07869 | 2/20 | 0.36 |
| ▸ | CASP1 | P29466 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2003571 | 0.85 | PPARD (0.40) | KDM4EGAAALDH1A1MAPTMEN1 | |
| SCHEMBL2003981 | 0.83 | PTGDR2 (0.47) | KDM4EGAAALDH1A1MAPTMEN1 | |
| SCHEMBL2006458 | 0.78 | PTGDR (0.60) | PTGDR2PTGDRCYP3A4 | |
| SCHEMBL2000430 | 0.76 | PTGDR2 (0.42) | KDM4EGAAALDH1A1MAPTMEN1 | |
| SCHEMBL2005251 | 0.71 | PTGDR (0.55) | KDM4EALDH1A1MAPTMEN1KMT2A | |
| SCHEMBL4052655 | 0.70 | MTNR1A (0.65) | KDM4EGAAALDH1A1MAPTMEN1 | |
| SCHEMBL13742641 | 0.67 | FFAR1 (0.56) | GAAPTGDR2CHRM1PPARDCA2 | |
| SCHEMBL12570796 | 0.67 | CYP3A4 (0.50) | KDM4EGAAALDH1A1MAPTMEN1 | |
| SCHEMBL11331485 | 0.66 | KDM4E (0.63) | KDM4EGAAALDH1A1MAPTMEN1 | |
| SCHEMBL10899796 | 0.66 | CA2 (0.56) | GAAALDH1A1MEN1KMT2APPARD |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2164828-B1 | COMPOUNDS AS CRTH2 AND/OR PGD2 RECEPTORS MODULATORS AND THEIR USE FOR TREATING ASTHMA AND ALLERGIC INFLAMMATION | AMGEN INC (US) | 2013-03-27 | — | — | EP | disclosed |
| EP-2164828-B1 | COMPOUNDS AS CRTH2 AND/OR PGD2 RECEPTORS MODULATORS AND THEIR USE FOR TREATING ASTHMA AND ALLERGIC INFLAMMATION | AMGEN INC (US) | 2013-03-27 | — | — | EP | disclosed |
| US-7960567-B2 | Compounds and methods useful for treating asthma and allergic inflammation | AMGEN INC. (US) | 2011-06-14 | — | — | US | disclosed |
| US-7960567-B2 | Compounds and methods useful for treating asthma and allergic inflammation | AMGEN INC. (US) | 2011-06-14 | — | — | US | disclosed |
| US-7960567-B2 | Compounds and methods useful for treating asthma and allergic inflammation | AMGEN INC. (US) | 2011-06-14 | — | — | US | disclosed |
| EP-2164828-A2 | COMPOUNDS AS CRTH2 AND/OR PGD2 RECEPTORS MODULATORS AND THEIR USE FOR TREATING ASTHMA AND ALLERGIC INFLAMMATION | Amgen Inc. (US) | 2010-03-24 | — | — | EP | disclosed |
| US-20080312270-A1 | COMPOUNDS AND METHODS USEFUL FOR TREATING ASTHMA AND ALLERGIC INFLAMMATION | AMGEN INC. | 2008-12-18 | — | — | US | disclosed |
| US-20080312270-A1 | COMPOUNDS AND METHODS USEFUL FOR TREATING ASTHMA AND ALLERGIC INFLAMMATION | AMGEN INC. | 2008-12-18 | — | — | US | disclosed |
| US-20080312270-A1 | COMPOUNDS AND METHODS USEFUL FOR TREATING ASTHMA AND ALLERGIC INFLAMMATION | AMGEN INC. | 2008-12-18 | — | — | US | disclosed |
| WO-2008137027-A2 | COMPOUNDS AS CRTH2 AND/OR PGD2 RECEPTORS MODULATORS AND THEIR USE FOR TREATING ASTHMA AND ALLERGIC INFLAMMATION | AMGEN INC. (US) | 2008-11-13 | — | — | WO | disclosed |
| WO-2008137027-A2 | COMPOUNDS AS CRTH2 AND/OR PGD2 RECEPTORS MODULATORS AND THEIR USE FOR TREATING ASTHMA AND ALLERGIC INFLAMMATION | AMGEN INC. (US) | 2008-11-13 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080312270-A1 | COMPOUNDS AND METHODS USEFUL FOR TREATING ASTHMA AND ALLERGIC INFLAMMATION | CCL11, LTC4S, TSLP | KDM4E 2160/4885GAA 2651/4885ALDH1A1 495/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.